2-Ethyl-2-phenoxymethyl-propan-1,3-diol | 3897-83-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-Ethyl-2-phenoxymethyl-propan-1,3-diol
• 英文别名: 2-Ethyl-2-(phenoxymethyl)propane-1,3-diol
• CAS: 3897-83-4
• 化学式: C₁₂H₁₈O₃
• 分子量: 210.273
• InChiKey: ZCPWGHJTALRUBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-乙基-3-(苯氧基甲基)氧杂环丁烷 在 硫酸 作用下， 生成 2-Ethyl-2-phenoxymethyl-propan-1,3-diol
  参考文献：
  名称：

  Cheymol,J. et al., Bulletin de la Societe Chimique de France, 1965, p. 694 - 700

  摘要：

  DOI：

文献信息

• [EN] METHODS FOR TREATING PROSTATE CONDITIONS<br/>[FR] PROCÉDÉS POUR TRAITER DES TROUBLES DE LA PROSTATE
  申请人：PTC THERAPEUTICS INC

  公开号：WO2010138685A1

  公开（公告）日：2010-12-02

  Methods for treating prostate cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described. Methods for treating benign prostatic hyperplasia involving the administration of a compound that selectively inhibits pathological production of human VEGF are also described. The compound may be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
• [EN] METHODS FOR TREATING NEUROFIBROMATOSIS<br/>[FR] PROCÉDÉS POUR TRAITER LA NEUROFIBROMATOSE
  申请人：PTC THERAPEUTICS INC

  公开号：WO2010138695A1

  公开（公告）日：2010-12-02

  Methods for treating neurofibromatosis involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
• [EN] METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS<br/>[FR] PROCÉDÉS DE TRAITEMENT D'UN CANCER ET D'ÉTATS NON NÉOPLASIQUES
  申请人：PTC THERAPEUTICS INC

  公开号：WO2010138758A1

  公开（公告）日：2010-12-02

  Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.
• [EN] METHODS FOR TREATING KAPOSI SARCOMA<br/>[FR] MÉTHODES DE TRAITEMENT DU SARCOME DE KAPOSI
  申请人：PTC THERAPEUTICS INC

  公开号：WO2010138652A1

  公开（公告）日：2010-12-02

  Methods for treating Kaposi's sarcoma involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
• [EN] METHODS FOR TREATING BRAIN TUMORS<br/>[FR] PROCÉDÉS POUR TRAITER DES TUMEURS CÉRÉBRALES
  申请人：PTC THERAPEUTICS INC

  公开号：WO2010138659A1

  公开（公告）日：2010-12-02

  Methods for treating brain tumors involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatment.